Power-Pak C.E.
Advertisement
 Login Help  Forgot Password?
Professions: Topics:
September 7, 2010



For more CE topics, click here to go to uspharmacist.com


     
 
 

Read Lesson
Lesson

Submit Answers
Answer Questions

Tables
Tables

References
References

Appropriate and Safe Dosing of
Atypical Antipsychotics

Published: November 1, 2002
ACPE Lesson Expires: November 1, 2005


Provided through an unrestricted educational grant from


 

REFERENCES

  1. Gerlach J. Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria. Ann Clin Psychiatry. 2002;14:47-57.

  2. Marder SR. Approaching the adherence challenge. Program and abstract of the American Psychiatric Association 155th Annual Meeting; May 18-23, 2002; Philadelphia, Pa. Industry-supported Symposium No. 17A.

  3. Casey DE. Adverse effects profile of new antipsychotic agents. Program and abstract of the American Psychiatric Association 155th Annual Meeting; May 18-23, 2002; Philadelphia, Pa. Industry-supported Symposium No. 35C.

  4. Kane JM. Dose selection and comparator drugs in schizophrenia research. J Clin Psychiatry. 2001;62:29-32; discussion 33-34.

  5. Williams R. Optimal dosing with risperidone: updated recommendations. J Clin Psychiatry. 2001;62:282-289.

  6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Press; 1994.

  7. Dixon LB, et al. Conventional antipsychotic medications for schizophrenia. Schizophr Bull. 1995;21(4):1567-1577.

  8. Clozaril® (package insert). East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 1998.

  9. Beasley CM, Tollefson GD, Tran PV. Efficacy of olanzapine: an overview of pivotal clinical trials. J Clin Psychiatry. 1997;58:7-12.

  10. Beasley CM Jr, Sanger T, Satterlee W, et al. Olanzapine versus placebo: results of a double blind, fixed-dose olanzapine trial. Psychopharmacology (Berl). 1996;124:159-167.

  11. Seroquel® (package insert). Wilmington, Del: Zeneca Pharmaceuticals; November 1997.

  12. Geodon® (package insert). New York, NY: Pfizer; February 2002.

  13. Stahl SM. Psychopharmacology of Antipsychotics. London: Martin Dunitz Ltd; 1999:5.

  14. Seeman P, Tallerico T. Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry. 1999;156(6):876-884.

  15. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors: focus on newer generation compounds. Life Sciences. 2000;68:29-39.

  16. Kapur S, Zipursky R, Jones C, et al. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry. 2000;57:553-559.

  17. De Nayer A, Martin Jones A, Whiteford JL, Altman CA. Switching to quetiapine improves CGI and PANSS scores in patients with schizophrenia. Poster presented at: CINP XXIIIrd Congress; June 23-27, 2002; Montreal, Canada. Poster Number: P.2.W.020.

  18. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull. 1999;25:233-255.

  19. Velligan DI, Newcomer J, Pultz J, et al. Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res. 2002;53(3):239-248.

  20. Society for Neuroscience. Brain briefings: the prefrontal cortex and schizophrenia. Summer 1995.

  21. Tatsumi M, Jansen K, Blakely RD, Richelson E. Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol. 1999;368:277-283.

  22. Newman-Tancredi A, Verriele L, Touzard M, Millan MJ. Efficacy of antipsychotic agents at human 5-HT(1A) receptors determined by [3H]WAY100,635 binding affinity ratios: relationship to efficacy for G-protein activation. Eur J Pharmacol. 2001;428:177-184.
  23. Nutt, DJ. Putting the “A” in atypical: does alpha-2 adrenoceptor antagonism account for the therapeutic advantage of new antipsychotics? J Psychopharmacol. 1994;8:193-195.
  24. Freedman R. Nicotinic receptors and the genetics of schizophrenia and bipolar disorder. Program and abstracts of: American Psychiatric Association 155th Annual Meeting; May 18-23, 2002; Philadelphia, Pa.

  25. Tamminga CA. Glutamatergic transmission in schizophrenia. Program and abstracts of: American Psychiatric Association 155th Annual Meeting; May 18-23, 2002; Philadelphia, Pa.

  26. Araki H, Suemaru K, Gomita Y. Neuronal nicotinic receptor and psychiatric disorders: functional and behavioral effects of nicotine. Jpn J Pharmacol. 2002;88:133-138.

  27. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686-1696.

  28. Brecher M, Rak IW, Melvin K, et al. The long-term effect of quetiapine (Seroquel™) monotherapy on weight in patients with schizophrenia. Int J Psychiatry Clin Pract. 2000;4:287-291.

  29. Hägg S, Joelson L, Mjörndal T, et al. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry. 1998;59:294-299.

  30. Mir S, Taylor D. Atypical antipsychotics and hyperglycaemia. Int Clin Psychopharmacol. 2001;16:63-73.

  31. Newcomer JW, Henderson DC, Lebovitz HE, et al. Metabolic disturbances associated with antipsychotic use. J Clin Psychiatry. (Audiograph Series) 2001;4:1-24.

  32. Nyberg S, Eriksson B, Oxenstierna G, et al. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry. 1999;156:869-875.

  33. Duggan L, Fenton M, Dardness RM, et al. Olanzapine for schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 3, 2002. Available at: http://www.update-software.com/abstracts/ab001359.htm. Accessed September 9, 2002.

  34. Okubo Y, Suhara T. Receptor occupancy and antipsychotic drug action measured by PET and SPECT. Seishin Shinkeigaku Zasshi. 2001;103:329-340.

  35. Lieberman JA. Mechanism of action as predictor for clinical utility: lesson from schizophrenia research. Program and abstracts of: American Psychiatric Association 155th Annual Meeting; May 18-23, 2002; Philadelphia, Pa.

  36. Centorrino F, Price BH, Tuttle M, et al. EEG abnormalities during treatment with typical and atypical antipsychotics. Am J Psychiatry. 2002;159:109-115.

  37. Nyberg S, Chou YH, Halldin C. Saturation of striatal D2 dopamine receptors by clozapine. Int J Neuropsychopharmacol. 2002;5:11-16.

  38. Suhara T, Okauchi T, Sudo Y, et al. Clozapine can induce high dopamine D(2) receptor occupancy in vivo. Psychopharmacology (Berl). 2002;160:107-112.

  39. Kane JM. The new antipsychotics. J Prac Psych Behav Hlth. November,1997:343­354.

  40. Kennedy E, Song F, Hunter R, et al. Risperidone versus typical antipsychotic medication for schizophrenia (Cochrane Review). Cochrane Database Syst Review 2000;(2):CD000440.
  41. Gilbody SM, Bagnall AM, Duggan L, Tuunainen A. Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 3, 2002. Oxford: Update Software. Available at: http://www.update-software.com/abstracts/ab002306.htm. Accessed Septermer 9, 2002.

  42. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997; 58:538-546.

  43. Csernansky JG, Mahmoud R, Brenner R. The Risperidone-USA-79 Study Group: a comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. J Appl Physiol. 2001;91:755-761.

  44. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2001;158:765-774.

  45. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997;17:407-418.

  46. Ho BC, Miller D, Nopoulos P, Anreasen NC. A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. J Clin Psychiatry. 1999;60:658-663.

  47. Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry. 1997;154:457-465.

  48. Stahl SM. Psychopharmacology of Antipsychotics. London: Martin Dunitz Ltd; 1999:101.

  49. Gefvert O, Lundberg T, Wieselgren IM, et al. D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur Neuropsychopharmacol. 2001;11:105-110.

  50. Bagnall AM, Lewis RA, Leitner ML. Ziprasidone for schizophrenia and severe mental illness (Cochrane Review). In: The Cochrane Library, Issue 4. Avaliable at: http://www.update-software.com/abstracts/ab001945.htm. Accessed September 30, 2002.

  51. Weiden PJ. Ziprasidone: a new atypical antipsychotic. J Psychiatric Prac. 2001;7(2):145-154.

  52. Koro CE, Fedder DO, L'Italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ. 2002;325(7358):243.

 

BACK to TOP

 
 
 
       
 
Copyright © 1997 - 2010 Postgraduate Healthcare Education LLC unless otherwise noted.
All rights reserved. Reproduction in whole or in part without permission is prohibited. Privacy Policy